George Washington University, Washington, District of Columbia, USA.
Coagulation and Blood Research Program, U.S. Army Institute of Surgical Research, Fort Sam Houston, Texas, USA.
Transfusion. 2021 Jan;61(1):167-177. doi: 10.1111/trf.16096. Epub 2020 Dec 8.
Platelets pose the greatest transfusion-transmitted infectious risk among blood products. Refrigeration of platelets can mitigate bacterial contamination and extend platelet shelf life. Implementation of pathogen reduction technologies (PRTs) at blood banks has become increasingly popular to protect against emerging and reemerging infectious diseases. In this study, we sought to evaluate the effects of Intercept PRT on platelets collected on different platforms and cold-stored for up to 21 days in plasma and platelet additive solution (PAS).
Double-dose apheresis platelets were collected with use of a Trima or Amicus system into either 100% plasma or 65% InterSol PAS/35% plasma and split equally between two bags. One bag served as control, while the other received Intercept PRT treatment. Bags were stored unagitated in the cold and evaluated on Days 1, 7, 14, and 21 to assess platelet metabolism, activation, aggregation, and clot formation and retraction.
By Day 14 of storage, lactate levels reached approximately 13 mmol/L for all samples irrespective of Intercept treatment. Mean clot firmness dropped from the 62.2- to 67.5-mm range (Day 1) to the 28.4- to 51.3-mm range (Day 21), with no differences observed between groups. Clot weights of Intercept-treated Trima/plasma samples were significantly higher than control by Day 14 of storage (P = .004), indicating a reduced clot retraction function. Intercept treatment caused a higher incidence of plasma membrane breakdown in plasma-stored platelets (P = .0013; Trima/plasma Day 14 Control vs Intercept).
Intercept treatment of platelets and subsequent cold storage, in plasma or PAS, results in comparable platelet metabolism platelets for up to 14 days of storage but altered clotting dynamics. Pathogen-reduced platelets with an extended shelf life would be beneficial for the deployed setting and would greatly impact transfusion practice among civilian transfusion centers.
血小板是血液制品中传播传染性风险最大的成分。冷藏血小板可以减轻细菌污染并延长血小板的保存期。在血库中实施病原体减少技术(PRT)已越来越受欢迎,以防止新发和再现传染病。在这项研究中,我们试图评估在不同平台收集的血小板在血浆和血小板添加剂溶液(PAS)中冷藏长达 21 天并接受 Intercept PRT 处理的效果。
使用 Trima 或 Amicus 系统采集双倍剂量的单采血小板,分别将其放入 100%血浆或 65% InterSol PAS/35%血浆中,并将其平均分为两个袋子。一个袋子作为对照,另一个袋子接受 Intercept PRT 处理。将袋子在冷处不摇动储存,并在第 1、7、14 和 21 天进行评估,以评估血小板代谢、激活、聚集和凝块形成和回缩。
无论是否接受 Intercept 处理,所有样本在储存的第 14 天,乳酸水平均达到约 13mmol/L。从第 1 天的 62.2-67.5mm 范围,平均凝块硬度下降到第 21 天的 28.4-51.3mm 范围,各组之间没有差异。储存第 14 天,Intercept 处理的 Trima/血浆样本的凝块重量明显高于对照组(P=0.004),表明凝块回缩功能降低。Intercept 处理导致在血浆储存的血小板中血浆膜破裂的发生率更高(P=0.0013;Trima/血浆第 14 天对照组与 Intercept)。
在血浆或 PAS 中对血小板进行 Intercept 处理并随后冷藏可使血小板的代谢在长达 14 天的储存时间内保持相似,但会改变凝血动力学。具有延长保质期的病原体减少的血小板将有益于部署环境,并极大地影响民用输血中心的输血实践。